Interpace Diagnostics has obtained $12.2 million in net proceeds from its public offering of 9.9 million shares of common stock, common warrants to buy 12.5 million shares and prefunded warrants to buy 2.6 million shares. The net proceeds will be used as working capital, as well as for general corporate functions, payment of legacy contract sales organization obligations and trade payables.
Public offering brings in $12.2M for Interpace Diagnostics
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.